Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Alten, Rieke ^a   Gomez Reino, Juan ^b   Durez, Patrick ^c   Beaulieu, Andre ^d   Sebba, Anthony ^e   Krammer, Gerhard ^f   Preiss, Ralph ^f   Arulmani, Udayasankar ^f   Widmer, Albert ^f   Gitton, Xavier ^f   Kellner, Herbert ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Instituto de Salud Carlos III   (Spain)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d Centre de Rheumatologie St Louis   (Canada)

^e Arthritis Associates   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Health Plaza ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; METHOTREXATE; PARACETAMOL; PLACEBO; PLASMA PROTEIN; PREDNISONE; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT INVENTORY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-1BETA; MALE; METHOTREXATE; MIDDLE AGED;

EID: 80052189130     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-153     Document Type: Article

References (15)

1. Rheumatoid arthritis. Lee DM, Weinblatt ME, Lancet 2001 358 903 911 10.1016/S0140-6736(01)06075-5 11567728 (Pubitemid 32900579)
2. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Dayer JM, Rheumatology (Oxford) 2003 42 suppl 2 i3 10
3. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Tak PP, Bresnihan B, Arthritis Rheum 2000 43 2619 2633 10.1002/1529-0131(200012)43:12<2619::AID- ANR1>3.0.CO;2-V 11145019 (Pubitemid 32001727)
4. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Lettesjö H, Nordström E, Ström H, Nilsson B, Glinghammar B, Dahlstedt L, Möller E, Scand J Immunol 1998 48 286 292 10.1046/j.1365-3083.1998.00399.x 9743215 (Pubitemid 28416972)
5. Anakinra for rheumatoid arthritis. Mertens M, Singh J, Cochrane Database of Systemic Reviews 2009 1 D005121
6. Use of canakinumab in the cryopyrin-associated periodic syndrome. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN, Canakinumab in CAPS Study Group, N Engl J Med 2009 360 2416 2425 10.1056/NEJMoa0810787 19494217
7. Evaluation of Safety and Preliminary Efficacy of Canakinumab (ACZ885), a New IL-1-Beta Blocking Monoclonal Antibody, in Children with Systemic Juvenile Idiopathic Arthritis (sJIA) [Abstract]. Ruperto N, Quartier P, Wulffraat N, Woo P, Loy A, Mouy R, Bader-Meunier B, Prakken B, Noseda E, Belleli R, Lecot J, Rordorf C, Martini A, PRINTO, Arthritis Rheum 2009 60 suppl 10 1 Abstract no.2055 19116910
8. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, Arulmani U, Sallstig P, Schlesinger N, Arthritis Rheum 2010 62 3064 3076
9. Efficacy of Canakinumab (ACZ885), a Fully Human Anti-Interleukin(IL)- 1beta Monoclonal Antibody, in the Prevention of Flares in Gout Patients Initiating Allopurinol Therapy [Abstract]. Schlesinger N, Lin H-Y, De Meulemeester M, Nasonov EL, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A, Arthritis Rheum 2010 62 suppl 10 1 S872 21204100
10. The human anti-IL-1beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T, Arthritis Res Ther 2008 10 67 10.1186/ar2438 18534016 (Pubitemid 351903406)
11. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG, Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796 (Pubitemid 18091653)
12. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F, Arthritis Rheum 1992 35 498 502 10.1002/art.1780350502 1575785
13. Joint counts in routine practice [Editorial]. Scott DL, Rheumatology (Oxford) 2003 42 919 923 10.1093/rheumatology/keg235 (Pubitemid 37220955)
14. Update on biology: uric acid and the activation of immune and inflammatory cells. Martinon F, Curr Rheumatol Rep 2010 12 135 141 10.1007/s11926-010-0092-3 20425023
15. The pathogenesis of bone erosions in gouty arthritis. Schlesinger N, Thiele GR, Ann Rheum Dis 2010 69 1907 1912 10.1136/ard.2010.128454 20705636